Avelumab Maintenance in Advanced Urothelial Carcinoma: Key Insights
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community oncologists.
Shilpa Gupta, MD, director, genitourinary medical oncology, Taussig Cancer Institute, and co leader of the genitourinary oncology program at Cleveland Clinic, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 (NCT02603432) trial for community oncologists, particularly regarding the impact of avelumab (Bavencio) as first-line maintenance.
Findings presented at the 2025 Genitourinary Cancers Symposium showed that when given with best supportive care (BSC) in the first-line maintenance setting, avelumab led to improved overall survival and progression-free survival rates compared with BSC alone in patients with advanced urothelial carcinoma, regardless of diabetes mellitus status.
These findings come from exploratory analyses from the phase 3 JAVELIN Bladder 100 trial. The study included patients with unresectable locally advanced or metastatic urothelial carcinoma who remained progression free after 4 to 6 cycles of first-line platinum-based chemotherapy.
Once enrolled in the trial, patients were assigned to receive frontline maintenance with avelumab and BSC or BSC alone. The exploratory analysis evaluated long-term efficacy and safety outcomes within the subgroups of patients with or without documented diabetes mellitus at randomization.
Transcription:
0:10 | From the community oncology perspective, I think this is important information for them to know that if patients cannot get [enfortumab vedotin with pembrolizumab] in the frontline, this is a very reasonable regimen.
0:23 | And some of the reasons patients may not be able to get [enfortumab vedotin with pembrolizumab] or if they have severe baseline peripheral neuropathy. So, in that case, they could use gemcitabine, [carboplatin], followed by nivolumab [Opdivo] maintenance.
REFERENCE:
- Gupta S, Grivas P, Park SH, et al. Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): long-term outcomes from JAVELIN Bladder 100. J Clin Oncol. 2025;43(suppl 5):869. doi:10.1200/JCO.2025.43.5_suppl.869
